The relationship between the BRAF$^{V600E}$ mutation in papillary thyroid microcarcinoma and clinicopathologic factors

Sun Yi Choi1, HeonSoo Park2, Myung Koo Kang2, Dong Kun Lee2, Kang Dae Lee3, Hyoung Shin Lee3, Sung Won Kim3, Eun Nam Lee4 and Jong Chul Hong2*

Abstract
Background: The BRAF$^{V600E}$ mutation, which accounts for about 60–80% papillary thyroid carcinoma (PTC), has been identified as a prognostic marker for risk stratification of PTC patients. However, the BRAF$^{V600E}$ mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear.

Methods: We performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the prevalence of the BRAF$^{V600E}$ mutation. The associations between the BRAF$^{V600E}$ mutation and clinicopathologic characteristics were analyzed.

Results: The BRAF$^{V600E}$ mutation was observed in 72 patients (71.3%). There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAF$^{V600E}$ mutant group and wild group.

Conclusions: The BRAF$^{V600E}$ mutation is not significantly associated with prognostic factors in PTMC.

Keywords: BRAF mutation, Papillary thyroid microcarcinoma, Prognosis

Background
Thyroid carcinoma is the most common endocrine malignancy and its prevalence is increasing. Recent extensive use of thyroid ultrasound has led to the increased detection of non-palpable thyroid nodules. Papillary thyroid carcinoma (PTC) is the most common type of endocrine malignancy followed by follicular thyroid carcinoma. The prevalence of PTC is rapidly increasing and currently accounts for >95% of all thyroid carcinomas in Korea [1]. Papillary thyroid microcarcinoma (PTMC), a form of PTC, is defined by the World Health Organization as a tumor measuring 1 cm or less in its greatest dimension. Based on the high incidence of PTMC in autopsy studies, its prognosis is generally favorable and sometimes it is truly indolent and non-progressive [2]. However, it has been reported that PTMC may have a metastatic potential similar to that of their clinically detectable counterparts [3-5]. Thus, estimate of prognosis as well as detection of PTMC has become an important issue.

The BRAF$^{V600E}$ mutation, which accounts for about 60–80% of PTCs, has been identified as a promising prognostic marker for risk stratification of PTC patients in Korea [4]. However, uncertainties still exist due to the discordance of studies. Some studies show a significant relationship between the BRAF$^{V600E}$ mutation and the high-risk clinicopathologic characteristics of PTC [4,6]. However, other studies have failed to find a significant association between the BRAF$^{V600E}$ mutation and high-risk clinicopathologic characteristics [5,7]. With regards to PTMC, studies show no significant correlation [7]. Nevertheless, considering its nature, further study of the characteristics of PTMC through BRAF$^{V600E}$ mutational status analysis is needed. We investigated the prevalence of the BRAF$^{V600E}$ mutation and analyzed the relationship between the BRAF$^{V600E}$ mutation and clinicopathologic factors in PTMC.
Methods

Patients

The study included review of 253 patients who had undergone thyroid cancer surgery between June 2011 and July 2012 at the department of Otolaryngology-Head and Neck surgery, Dong-A Medical Center, Busan, Korea. Most patients underwent total thyroidectomy with general anesthesia. In case of unifocal intrathyroidal microcarcinoma with no evidence of cervical lymph node metastasis in preoperative ultrasonography, we conducted thyroid lobectomy. Central compartment neck dissection was performed when an enlarged lymph node or invasion of the thyroid capsule was detected during surgery. Modified radical neck dissection was conducted in cases of lateral lymph node metastasis. Of these 253 patients, 101 patients diagnosed with conventional PTMC were enrolled in the study. Informed consent for the evaluation of patients diagnosed with conventional PTMC were enrolled in the study. Informed consent for the evaluation of BRAFV600E mutation in PTMC was obtained from all PTMC patients. We studied the prevalence of the BRAFV600E mutation and evaluated its correlations with diverse clinicopathologic features of PTMC.

DNA extraction and the BRAFV600E mutation analysis

We performed the BRAFV600E mutation analysis on paraffin embedded sections of primary tumors obtained after thyroidectomy. Genomic DNA was extracted from 10 µm-thick sections of 10% neutral formalin-fixed paraffin-embedded tumor tissue blocks using the High Pure PCR Template Preparation Kit (Roche Applied Science, Germany). The concentration and purity of the extracted DNA were determined by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA). The extracted DNA was stocked at −20°C until further use.

The assays for the detection of the BRAFV600E mutation were performed using the PNACLamp™-BRAF Mutation Detection kit (Panagene, Inc., Daejeon, Korea). All reactions were done in 20-µL volumes using template DNA, primer and peptide nucleic acid (PNA) probe set, and PCR master mix. All needed reagents were included with the kit. Real-time PCR reaction of PNA-mediated clamping PCR was performed using a CFX 96 (Bio-Rad, USA). PCR cycling conditions were a 5 min hold at 94°C followed by 40 cycles of 94°C for 30 sec, 70°C for 20 sec, 63°C for 30 sec, and 72°C for 30 sec. In this assay, PNA probes and DNA primers are used together in the clamping reaction. Positive signals are detected by intercalation of fluorescent dye. The PNA probe sequence is complementary to wild-type DNA to suppress amplification of wild-type target, thereby enhancing preferential amplification of mutant sequences by competitively inhibiting DNA primer binding to wild-type DNA. PCR efficiency was determined by measuring the threshold cycle (Ct) value. Ct values for the control and mutation assays were obtained by observing the amplification plots. The delta Ct (ΔCt) value was calculated as follows, ensuring that the sample and Standard Ct values were from the tested sample and clamping control sample: [Standard Ct]-[Sample Ct] = ΔCt. The cut-off ΔCt was defined as 2.0 for the BRAFV600E mutation (Figure 1).

Statistical analysis

To evaluate the association between BRAFV600E mutation and prognostic variables, we used χ² or Fisher’s exact test and logistic regression using the SPSS 18.0 program (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as P < 0.05.

Results

All included patients had PTMC confirmed on the surgical specimen. Of 101 patients, BRAFV600E mutation in PTMC was observed in 72 patients, indicating a prevalence of 71.3%. The number of patients aged ≥45 years were 76 [mutant: 56 (77.8%), wild: 20 (69.0%)]; and showed no statistical significance. The female sex was dominant in PTMC patients (89.1%); however, there was no statistical significance with BRAFV600E mutation. There were 31 patients with multifocality [mutant: 22 (30.6%), wild: 9 (31.0%)], 53 patients with extrathyroidal extension [mutant: 37 (51.4%), wild: 16 (55.2%)], and 22 patients with combined Hashimoto’s thyroiditis [mutant: 14 (19.4%), wild: 8 (27.6%)]. These three factors were not significantly related. There were 48 T1a patients [mutant: 36 (50.0%), wild: 12 (41.4%)], 52 T3 patients [mutant: 35 (48.6%), wild: 17 (58.6%)], and 1 T4a patient [mutant: 1 (1.4%), wild: 0 (0%)]. There were 18 patients with nodal metastasis; among these, 11 were N1a [mutant: 8 (11.1%), wild: 3 (10.3%)]; and 7 were N1b [mutant: 3 (4.2%), wild: 4 (13.8%)]. The T and N staging were not significantly related to BRAFV600E mutation (Table 1). Distant metastasis to the lung was found in one patient with wild type and it was not significantly relevant with BRAFV600E.

In summary, as shown in Tables 1 and 2, there were no statistically significant correlations with regards to age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAFV600E mutant and wild-type groups.

Discussion

PTMC belongs to the low-risk well-differentiated PTC group of carcinomas, which are probably of little clinical significance and do not affect patient survival. However, PTMC may be associated with lymph node metastases at presentation and/or loco-regional recurrence during follow-up [8]. Xing et al. investigated the relationship between BRAFV600E mutation and PTC-related mortality in 1,849 patients. The overall mortality was 5.3% vs. 1.1% (mutant vs. wild, P < 0.001). They showed the BRAFV600E mutation was significantly associated with increased
cancer-related mortality among patients with PTC [9]. In their study, it is uncertain that the BRAFV600E mutation is correlated with poor prognostic factors in PTMC. In the current study, we investigated the incidence of BRAFV600E mutation and the clinicopathologic relationship between mutant and wild-type groups of PTMC patients.

BRAF mutations are the most common genetic alterations in PTC. These mutations activate the RAS/RAF/mitogen-activated protein kinase pathway and result in the malignant transformation of cells. The T1779A point mutation in BRAF exon 15, resulting in a V600E amino acid substitution, is the most common and represents more than 90% of all the mutations found in the BRAF gene [10]. In Korea, the BRAFV600E mutation has been reported to be present in about 60–80% of PTC, which is higher than what is reported in other countries [4-7,10]. In this study, the BRAFV600E mutation was observed in 72 PTMC patients (71.3%). Guan et al. reported that the BRAFV600E mutation was found in 69% of PTC cases in high iodine intake areas and 53% in normal iodine intake areas \( (P < 0.0001) \) [11]. The authors think that Koreans eat iodine-rich diet, which increases the prevalence of the BRAFV600E mutation in PTC. Further study is needed to evaluate the association between BRAFV600E mutation and the iodine-rich diet in the Korean population.

In our study, we did not find a significant relationship between BRAFV600E mutation and clinicopathologic characteristics such as older age, gender, Hashimoto thyroiditis, T staging, nodal metastasis, multifocality, extrathyroidal extension, and distant metastasis. Based on these results, it seems that the BRAFV600E mutation is not related to the prognostic factors for PTMC that determine the invasiveness of the tumors.

Several studies have shown an association between the BRAFV600E mutation and prognostic factors in PTC. Kebebew et al. reported the BRAFV600E mutation was associated with older age \( (P = 0.0381) \) [6]. However, Kim et al. [4] and Lee et al. [12] revealed that age was not associated

---

**Figure 1** The assays for the detection of the BRAFV600E mutation. (A) In a patient with left thyroid nodule, the \( \Delta Ct-1 \) was measured as -2.17, and was identified as wild-type. (B) In another patient with right thyroid nodule, \( \Delta Ct-1 \) was measured as 8.86, and was identified as mutant type.
### Table 1: Relationship between the BRAFV600E mutation and clinicopathologic factors in papillary thyroid microcarcinoma

| Total, n(%) | BRAFV600E mutation, n (%) | \(\chi^2\) | P value |
|-------------|---------------------------|-----------|--------|
|             | Mutant (n = 72) | Wild (n = 29) |               |
| Age         |               |                     |               |
| <45 years   | 25(24.8)      | 16(22.2)            | 9(31.0)      | 0.862 | 0.353 |
| ≥45 years   | 76(75.2)      | 56(77.8)            | 20(69.0)      |       |      |
| Gender      |               |                     |               |
| Female      | 90(89.1)      | 63(87.5)            | 27(93.1)      |       |      |
| Male        | 11(10.9)      | 9(12.5)             | 2(6.9)        | 0.669 | 0.413 |
| Multifocality |               |                     |               |
| No          | 70(69.3)      | 50(69.4)            | 20(69.0)      |       |      |
| Yes         | 31(30.7)      | 22(30.6)            | 9(31.0)       |       |      |
| Extrathyroidal extension |               |                     |               |
| No          | 48(47.5)      | 35(48.6)            | 13(44.8)      | 0.002 | 0.962 |
| Yes         | 53(52.5)      | 37(51.4)            | 16(55.2)      |       |      |
| Hashimoto thyroiditis |               |                     |               |
| Not combined | 79(78.2)      | 58(80.6)            | 21(72.4)      |       |      |
| Combined    | 22(21.8)      | 14(19.4)            | 8(27.6)       | 0.804 | 0.37  |
| T staging   |               |                     |               |
| T1a         | 48(47.5)      | 36(50.0)            | 12(41.4)      |       |      |
| T3          | 52(51.5)      | 35(48.6)            | 17(58.6)      |       |      |
| T4a         | 1(1.0)        | 1(1.4)              | 0(0)          | 1.128 | 0.569 |
| Nodal metastasis |               |                     |               |
| N0          | 83(82.2)      | 61(84.7)            | 22(75.9)      |       |      |
| N1a         | 11(10.9)      | 8(11.1)             | 3(10.3)       |       |      |
| N1b         | 7(6.9)        | 3(4.2)              | 4(13.8)       |       |      |
| Distant metastasis |               |                     |               |
| No          | 100(99.0)     | 72(100.0)           | 28(96.6)      |       |      |
| Yes         | 1(1.0)        | 0(0.0)              | 1(3.4)        |       |      |

### Table 2: Summary of logistic regression for variables predicting the BRAFV600E mutation in PTMC

| Variables | B     | SE    | Wald | Df | P value | Odds ratio 95% confidence interval |
|-----------|-------|-------|------|----|---------|-----------------------------------|
| Age (1 = <45, 0 = ≥45) | -0.541 | 0.535 | 1.024 | 1  | 0.312   | 0.582 2.094 1.661 |
| Gender (1 = female, 0 = male) | -0.673 | 0.854 | 0.621 | 1  | 0.431   | 0.510 2.720 |
| Multifocality (1 = no, 0 = yes) | -0.007 | 0.512 | 0.000 | 1  | 0.989   | 0.993 2.064 |
| Extrathyroidal extension (1 = no, 0 = yes) | 0.101 | 0.485 | 0.044 | 1  | 0.835   | 1.106 2.860 |
| Hashimoto thyroiditis (1 = not combined, 0 = combined) | 0.481 | 0.532 | 0.817 | 1  | 0.366   | 1.617 0.570 4.586 |
| Nodal metastasis (Ib) | -      | -     | 2.636 | 2  | 0.268   | -      -      -      |
| Nodal metastasis (1 = N0, 0 = NIa) | 1.384 | 0.855 | 2.622 | 1  | 0.105   | 3.992 0.747 21.325 |
| Nodal metastasis (1 = N1a, 0 = N1b) | 1.303 | 1.053 | 1.530 | 1  | 0.216   | 3.680 0.467 29.005 |
| Constant | -0.015 | 1.230 | 0.000 | 1  | 0.991   | 0.986 1.000 1.000 |

*Reference group.*
with the BRAFV600E mutation. In our study, the prevalence of mutation in patients aged ≥45 years was higher than in wild-type patients (77.8% vs. 69%, \( P = 0.353 \)). However, there was no significant association in patients with old age. Kim et al. [4] and Xu et al. [13] showed the BRAFV600E mutation was associated with male gender. We found a higher prevalence of mutation in the male gender (12.5% vs. 6.9%, \( P = 0.413 \)), although this is not statistically significant due to the small number of male patients. Further, other reports showed no association between the BRAFV600E mutation and male gender [5-7,12]. Lim et al. reported that the BRAFV600E mutation was associated with extrathyroidal extension and multifocality [14]. Kim et al. showed no significant relationship between the BRAFV600E mutation and extrathyroidal extension and multifocality [7]. Our results also showed no relationships (\( P > 0.05 \)). However, in the study by Park et al., multifocality was associated with the BRAFV600E mutation [12]. Lim et al. reported a significant association between the BRAFV600E mutation and Hashimoto thyroiditis [14]. In this study, we could not find these significant associations. Several studies have reported that lymph node metastasis was significantly higher in patients with the BRAFV600E mutation [4,6,12,14]. In our result, lymph node metastasis had no significant association with the BRAFV600E mutation (15.3% vs. 24.1%, \( P = 0.226 \)). Ahn et al. [5] and Kim et al. [7] also found that the lymph node metastasis did not differ significantly between patients with and without the BRAFV600E mutation.

Against expectations, nodal metastasis and distant metastasis showed a slight negative association with BRAFV600E mutation. This result seems to be due to the small sample size and short follow-up period time. Therefore, oncologic outcomes such as recurrence, metastasis, and survival rate could not be observed. Further, the higher incidence of BRAFV600E mutation in Korea may have had an effect on the study results. Future studies with larger patient groups are needed to evaluate the oncologic outcomes.

Conclusions

In this study, we have shown that the prevalence of the BRAFV600E mutation was 71.3% in 101 PTMC patients in Korea. The BRAFV600E mutation was not associated with prognostic factors in patients with PTMC.

Consent

Our study is retrospective study, and all of our patients agreed to us using their medical information.

Abbreviations

Ct: Threshold cycle; PNA: Peptide nucleic acid; PTC: Papillary thyroid carcinoma; PTMC: Papillary thyroid microcarcinoma.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JCH organized all of the study. HSP, MKH, DKL, KDL, HSL, SWK and ENL participated in the study design and revised the manuscript. SYC drafted and wrote this manuscript. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by research funds from Dong-A University.

Author details

1Dong-A University College of Medicine, 3-1 Dongdahm-dong, Busan, Seo-Gu 602-715, South Korea. 2Department of Otolaryngology-Head and Neck Surgery, Dong-A University College of Medicine, 3-1 Dongdahm-dong, Busan, Seo-Gu 602-715, South Korea. 3Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, Ann-Nam Dong 34, Busan, Seo-Gu 602-702, South Korea. 4Department of Nursing, Dong-A University College of Medicine, Busan, South Korea.

Received: 4 September 2013 Accepted: 9 November 2013
Published: 14 November 2013

References

1. Ahn HY, Park YJ: Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med 2009, 77:357–342.
2. Rassael H, Thompson LD, Heffess CS: A rationale for conservative management of microscopic papillary carcinoma of the thyroid gland: a clinicopathologic correlation of 90 cases. Eur Arch Otorhinolaryngol 1998, 255:862–867.
3. Tufano RP, Bishop, JHo W: Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012, 122:1634–1640.
4. Kim SJ, Lee KE, Myjong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK: BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2013, 36:310–317.
5. Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY: Incidence and clinical characteristics of thyroid cancer in Korea. Ann Surg 2009, 249:198–203.
6. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246:466–470.
7. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Yoon YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 2005, 63:588–593.
8. Pazatou-Paraytou K, Capasso M, Pacini F: Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007, 17:1085–1092.
9. Xing M, Alzaharni AS, Cano KA, Vioa D, Elisei R, Bendivla Y, Vip L, Mian C, Vanello F, Tuttle RM, Robenhtok F, Fagin JA, Puependu E, Faguzola L, Czarnicka A, Jaizabi R, O’Neill CJ, Szpak MS, Larm AK, Risco-Esquerre G, Santisteban P, Nakayama H, Tufano RP, Piti SL, Zeiger MA, Westa WH, Clark DP, Clifton-Bithell R, Sidentorsky D, Ladenson PW, et al: Association between BRAF(V600E) mutation and mortality in patients with papillary thyroid carcinoma. JAMA 2013, 309:1493–1501.
10. Frasca F, Nucera C, Polletti G, Gangi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trinchero M, Fonzo B, Efferore A, Viglenti R: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15:191–205.
11. Gnan H, Ji M, Rao K, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M: Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009, 94:1612–1617.
12. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W: Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009, 16:240–245.
13. Xu X, Quirós RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63:4561–4567.
14. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY: Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid carcinoma: a subgroup analysis of 3130 cases in a single center. Thyroid 2013, 23(11):1423–1430.